학술논문

KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)
Document Type
Journal
Source
ANNALS OF ONCOLOGY; DEC 2021, 32 pS1444-pS1445, 2p. Supplement: 7
Subject
Language
English
ISSN
15698041